# Unraveling the mechanisms of slack channel mutations in epileptic disorders

**Authors:** Yue Wei, Aqeela Zahra, Qun Wang, Jianping Wu

PMC · DOI: 10.1186/s42494-026-00246-6 · Acta Epileptologica · 2026-03-02

## TL;DR

This paper explores how mutations in the KCNT1 gene, which encodes a key potassium channel, contribute to epilepsy and how these mutations affect brain function.

## Contribution

The paper provides a detailed overview of Slack channel biology and its role in epileptic disorders caused by KCNT1 mutations.

## Key findings

- Mutations in the KCNT1 gene impair potassium channel function, leading to seizures and epileptic disorders.
- The Slack channel is crucial for regulating neuronal excitability and is widely expressed in the central nervous system.
- Current therapeutic strategies are being explored to manage epilepsy caused by KCNT1 mutations.

## Abstract

Sodium-activated potassium channels (KNa) are extensively expressed throughout the central nervous system (CNS) and play a pivotal role in modulating neuronal excitability. The KNa achieve this by regulating the threshold for action potential initiation and the magnitude of post-hyperpolarization. The KCNT1 gene encodes the α subunit of KNa, also known as Slack channel, is crucial for governing the membrane excitability of neurons. Mutations in the KCNT1 gene impair the function of these potassium channels, leading to seizures and a spectrum of epileptic disorders. These conditions are often intractable and can range in severity from moderate to profound. This article delves into the subject of Slack channel detailing their architecture, physiological functions, distribution, and expression patterns, as well as their essential role in the nervous system. Additionally, we address the topic of epilepsy resulting from mutations in the KCNT1 gene and the therapeutic strategies currently available for managing these challenging conditions.

## Linked entities

- **Genes:** KCNT1 (potassium sodium-activated channel subfamily T member 1) [NCBI Gene 57582]
- **Diseases:** epilepsy (MONDO:0005027)

## Full-text entities

- **Genes:** FMR1 (fragile X messenger ribonucleoprotein 1) [NCBI Gene 2332] {aka FMRP, FRAXA, POF, POF1}, SCN1A (sodium voltage-gated channel alpha subunit 1) [NCBI Gene 6323] {aka DEE6, DEE6A, DEE6B, DRVT, EIEE6, FEB3}, KCNT1 (potassium sodium-activated channel subfamily T member 1) [NCBI Gene 57582] {aka DEE14, EIEE14, ENFL5, KCa4.1, KNa1.1, SLACK}, PLCB1 (phospholipase C beta 1) [NCBI Gene 23236] {aka DEE12, EIEE12, PI-PLC, PLC-154, PLC-I, PLC-beta-1}, SCN2A (sodium voltage-gated channel alpha subunit 2) [NCBI Gene 6326] {aka BFIC3, BFIS3, BFNIS, DEE11, EA9, EIEE11}, SLC12A5 (solute carrier family 12 member 5) [NCBI Gene 57468] {aka DEE34, EIEE34, EIG14, KCC2, hKCC2}, TBC1D24 (TBC1 domain family member 24) [NCBI Gene 57465] {aka DEE16, DFNA65, DFNB86, DOORS, EIEE16, EIM}, Kcnt1 (potassium channel, subfamily T, member 1) [NCBI Gene 227632] {aka C030030G16Rik, Slack, Slo2.2, slo2}, CHRNA2 (cholinergic receptor nicotinic alpha 2 subunit) [NCBI Gene 1135], Fmr1 (fragile X messenger ribonucleoprotein 1) [NCBI Gene 14265] {aka FMRP, Fmr-1}, SCN8A (sodium voltage-gated channel alpha subunit 8) [NCBI Gene 6334] {aka BFIS5, CERIII, CIAT, DEE13, EIEE13, MED}, KCNT2 (potassium sodium-activated channel subfamily T member 2) [NCBI Gene 343450] {aka DEE57, EIEE57, KCa4.2, KNa1.2, SLICK, SLO2.1}, SLC25A22 (solute carrier family 25 member 22) [NCBI Gene 79751] {aka DEE3, EIEE3, GC-1, GC1, NET44}, CHRNB2 (cholinergic receptor nicotinic beta 2 subunit) [NCBI Gene 1141] {aka EFNL3, nAChRB2}, CHRNA4 (cholinergic receptor nicotinic alpha 4 subunit) [NCBI Gene 1137] {aka BFNC, EBN, EBN1, NACHR, NACHRA4, NACRA4}, CTD (Coats disease) [NCBI Gene 1283]
- **Diseases:** VSD (MESH:D020886), brain atrophy (MESH:C566985), anxiety (MESH:D001007), atrophy of the frontal lobes (MESH:D001284), dysfunction of the central nervous system (MESH:D002493), OS (MESH:C567924), autistic-like behaviors (MESH:D001321), Infantile spasms syndrome (MESH:D013036), GOF (MESH:D015430), leukodystrophy (MESH:D007966), abnormalities of the white matter (MESH:D056784), focal epilepsy (MESH:D004828), WS West syndrome (MESH:D018980), SHE (MESH:D020183), refractory epilepsy (MESH:D000069279), functional disorder (MESH:D003291), FXS (MESH:D005600), EIMFS (MESH:D012640), LGS (MESH:D065768), neurological disorder (MESH:D009461), cardiotoxicity (MESH:D066126), epileptic disorders (MESH:D009358), DEE (MESH:C562695), tonic or dystonic posturing (MESH:D054972), Epilepsy (MESH:D004827), nutrient deficiencies (MESH:D007153), epileptic encephalopathies (MESH:D001927), intellectual disability (MESH:D008607), ADHD (MESH:D001289), AHPs (MESH:D000094025), metabolic acidosis (MESH:D000138), developmental impairment (MESH:D007805), obsessive-compulsive disorder (MESH:D009771), VANs (MESH:C536530), cortical dysplasia (MESH:D054220), developmental delay (MESH:D002658), ADNFLE (MESH:C579932), myoclonic encephalopathy (MESH:D004831), QT interval prolongation (MESH:D008133), mental and behavioral abnormalities (MESH:C564560), Dorsal root ganglion (MESH:D045888), cognitive and motor deficits (MESH:D003072)
- **Chemicals:** fat (MESH:D005223), beta-hydroxybutyrate (MESH:D020155), Ketones (MESH:D007659), thallium (MESH:D013793), clofilium (MESH:C022799), GABA (MESH:D005680), ketone bodies (MESH:D007657), ASM (-), Na+ (MESH:D012964), K+ (MESH:D011188), NADP (MESH:D009249), ASO (MESH:D016376), fatty acid (MESH:D005227), carbohydrate (MESH:D002241), Quinidine (MESH:D011802), Cl- (MESH:D002713), acetoacetate (MESH:C016635), ATP (MESH:D000255), VU0606170 (MESH:C000726207), NAD + (MESH:D009243), glucose (MESH:D005947)
- **Species:** Mus musculus (house mouse, species) [taxon 10090], Rattus norvegicus (brown rat, species) [taxon 10116], Homo sapiens (human, species) [taxon 9606]
- **Mutations:** G288S, Q270E, V271F, K629N, A259D, R398Q, G652V, R209C, A966T, P924L, R428Q, M516V, A934T, F346L, Y796H, R950Q, L274I, M896K
- **Cell lines:** SHE — Homo sapiens (Human), Childhood absence epilepsy, Transformed cell line (CVCL_HM06), HEK293 — Homo sapiens (Human), Transformed cell line (CVCL_0045)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12952033/full.md

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC12952033/full.md

## References

12 references — full list in the complete paper: https://tomesphere.com/paper/PMC12952033/full.md

---
Source: https://tomesphere.com/paper/PMC12952033